Home › Urothelial (Transitional Cell) Carcinoma › Virginia › Norfolk
Urothelial (Transitional Cell) Carcinoma clinical trials in Norfolk, VA
4 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Norfolk (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
RecruitingPhase 3
- Virginia Oncology Associates, Norfolk
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
RecruitingPhase 1/2
- Virginia Oncology Associates, Norfolk
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- USO - Virginia Oncology Associates, Norfolk
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RecruitingPhase 2/3
- Research Site, Norfolk
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Houston, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- San Antonio, TX11 studies
- Boston, MA11 studies
- Austin, TX10 studies
Other studies in Norfolk
- Breast Cancer16 studies
- Prostate Cancer8 studies
- Bladder Cancer8 studies
- Ovarian Cancer7 studies
- Non-Small Cell Lung Cancer7 studies
- Abdominal Aortic Aneurysm7 studies
- Heart Failure7 studies
- Cancer (all types)7 studies
- Cardiovascular Disease7 studies
- Spinal Muscular Atrophy6 studies
- Peripheral Arterial Disease5 studies
- Triple-Negative Breast Cancer5 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.